Verrica Pharmaceuticals Inc. (VRCA), a dermatology therapeutics company, continues to expect genomic and T-cell (immune response) data from its Phase 2 clinical trial studying VP-315 for the treatment of basal cell carcinoma this quarter.
The company also intends to schedule an End-of-Phase 2 meeting with the FDA in the first half of 2025 to discuss the next steps for advancing the development of VP-315 for the treatment of basal cell carcinoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com